At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed May 15, 2026 at 07:00 ET
Instil Bio reported Q1 2026 GAAP EPS of -$0.62, in line with the consensus estimate of -$0.59 (within the ±2% threshold). The company has $74.7M in cash, expected to fund operations beyond 2027, and is actively evaluating acquisition and in-licensing opportunities, though no specific transactions have been announced.
- GAAP net loss per share of $0.62 for Q1 2026, compared to $4.32 in Q1 2025
- Non-GAAP net loss per share of $0.32 for Q1 2026, compared to $1.32 in Q1 2025
- Cash, cash equivalents, restricted cash and marketable securities of $74.7M as of March 31, 2026
- Cash runway expected to fund current operating plan beyond 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access